If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 41 - 50 of 294
A Multicenter, Open-Label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-Cell Malignancies
This project is being done to test the safety of zilovertamab vedotin when given alone or
with nemtabrutinib, and to see how well zilovertamab vedotin works when given alone or with nemtabrutinib to treat B-cell cancers.
with nemtabrutinib, and to see how well zilovertamab vedotin works when given alone or with nemtabrutinib to treat B-cell cancers.
Protocol No
MERCK-MK2140-006-CLL-NHL
Categories
A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Adagrasib in Patients with KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 204)
A Phase 1/2 Study of VS-6766 in Combination with Adagrasib in Patients with KRAS G12C mutant NSCLC
Protocol No
VERASTEM-VS-6766-204
Categories
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
A phase 1 Study evaluating NX-5948, a BTK Degrader in Adults with Relapsed Refractory B-cell Malignancies
Protocol No
NURIX-NX-5948-301
Categories
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (
CAR-T Clinical trial in Subjects with Newly Diagnosed MM and for Whom HSCT is not planned
Protocol No
JNJ-68284528MMY3004CARTITUDE-5
A Phase 1 Study of NTX-301, an Oral DNMT1 Inhibitor, in Patients with MDS and AML
A phase 1 study of NTX-301 in patients with MDS and AML
Protocol No
UAB-19113-NTX-301
Categories
A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients With Treatment-refractory Mycobacterium Avium Complex Lung
Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease
Protocol No
INF-AN2-EBO-301-MAC
Categories
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Safety, Tolerability, and Efficacy of Intravenous AP-SA02 as an Adjunct to Best Available Antibiotic Therapy for the Treatment of Adults With Bacteremia Due t
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia (diSArm)
Protocol No
INF-ARMATA-DISARM
Categories
Expanded Access IND Protocol: Use of Tecovirimat (TPOXX) for Treatment of Human Orthopoxvirus Infections (CDC IND 116039, CDC IRB Protocol #6402)
TPOXX for Treatment of Human Orthopoxvirus Infections
Protocol No
INF-CDC-TPOXX-EA-IND-MONKEYPOX
Categories
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) (SANCTUARY)
Protocol No
NEPH-ALEXION-ALXN1210-202
Categories
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy
of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
Protocol No
NEPH-ELMEANAWY-OMEROS2
Categories